Telmisartan Market by Indication (Hypertension and Cardiovascular Risk Reduction) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2020–2027
The global telmisartan market was valued at $3,453 million in 2019, and is projected to reach $4,258 million by 2027, registering a CAGR of 3.4% from 2020 to 2027.
Telmisartan drug is a non-peptide angiotensin receptor blocker (ARB) used alone or in combination with other agents such as hydrochlorothiazide and amlodipine, for treatment of hypertension. Moreover, it is used in treatment of cardiovascular risk reduction. Telmisartan is available in tablets of different strengths such as 20, 40 and 80 mg tablets under the trade name Micardis. In addition, telmisartan tablet is available in generic forms. The daily dose of telmisartan for hypertension is 40 to 80 mg and for cardiovascular risk reduction it is 80 mg. These drugs are prescribed by a physician, and are available in retail stores, online pharmacies, and hospital pharmacies.
The growth of the global telmisartan market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension and cardiovascular is another major factor that fuels the growth of the market. In addition, surge in geriatric population and sedentary lifestyle act as key drivers of the global market. Moreover, increase in approval for abbreviated new drug application (ANDA) for manufacturing of generic telmisartan tablets and rise in cases of chronic kidney disease is expected to propel growth of telmisartan market. However, drug shortages are expected to restrain the growth of the telmisartan market. Conversely, surge in research related to telmisartan drug in emerging economies is expected to offer lucrative opportunities during the forecast period.
The global telmisartan market is segmented into indication, distribution channel, and region. On the basis of indication, the market is categorized into hypertension and cardiovascular risk reduction. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA
KEY BENEFITS FOR STAKEHOLDERS
By Indication
Telmisartan drug is a non-peptide angiotensin receptor blocker (ARB) used alone or in combination with other agents such as hydrochlorothiazide and amlodipine, for treatment of hypertension. Moreover, it is used in treatment of cardiovascular risk reduction. Telmisartan is available in tablets of different strengths such as 20, 40 and 80 mg tablets under the trade name Micardis. In addition, telmisartan tablet is available in generic forms. The daily dose of telmisartan for hypertension is 40 to 80 mg and for cardiovascular risk reduction it is 80 mg. These drugs are prescribed by a physician, and are available in retail stores, online pharmacies, and hospital pharmacies.
The growth of the global telmisartan market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension and cardiovascular is another major factor that fuels the growth of the market. In addition, surge in geriatric population and sedentary lifestyle act as key drivers of the global market. Moreover, increase in approval for abbreviated new drug application (ANDA) for manufacturing of generic telmisartan tablets and rise in cases of chronic kidney disease is expected to propel growth of telmisartan market. However, drug shortages are expected to restrain the growth of the telmisartan market. Conversely, surge in research related to telmisartan drug in emerging economies is expected to offer lucrative opportunities during the forecast period.
The global telmisartan market is segmented into indication, distribution channel, and region. On the basis of indication, the market is categorized into hypertension and cardiovascular risk reduction. Depending on distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of four regions is provided to determine the existing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
By Indication
- Hypertension
- Cardiovascular Risk Reduction
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Pharmacies
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Abbott Laboratories
- Aurobindo Pharma
- Boehringer Ingelheim International GmbH
- Cipla Inc.
- Glaxosmithkline Plc (GSK)
- Mylan N.V.
- Sanofi
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd. (Actavis Generics)
- Zydus Cadila
- Solco Healthcare
- Hikma Pharmaceuticals PLC
- Torrent Pharmaceuticals Ltd.
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five force analysis
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in geriatric population worldwide
3.5.1.2.Increase in healthcare expenditure worldwide coupled with surge in awareness towards treatment of high blood pressure
3.5.1.3.Rise in prevalence of hypertension across the globe
3.5.2.Restraint
3.5.2.1.Drug shortages of telmisartan tablets
3.5.3.Opportunities
3.5.3.1.High growth potential in developing economies
3.5.4.Impact analysis
3.6.Covid-19 Impact analysis on telmisartan market
CHAPTER 4:TELMISARTAN MARKET, BY INDICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Hypertension
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Cardiovascular risk reduction
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
CHAPTER 5:TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital pharmacies
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Drug stores and retail pharmacies
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Online pharmacies
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
CHAPTER 6:TELMISARTAN MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. telmisartan market, by indication
6.2.2.1.2.U.S. telmisartan market, by distribution channel
6.2.2.2.Canada
6.2.2.2.1.Canada telmisartan market, by indication
6.2.2.2.2.Canada telmisartan market, by distribution channel
6.2.2.3.Mexico
6.2.2.3.1.Mexico telmisartan market, by indication
6.2.2.3.2.Mexico telmisartan market, by distribution channel
6.2.3.North America market size and forecast, by indication
6.2.4.North America market size and forecast, by distribution channel
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany
6.3.2.1.1.Germany telmisartan market, by indication
6.3.2.1.2.Germany telmisartan market, by distribution channel
6.3.2.2.France
6.3.2.2.1.France telmisartan market, by indication
6.3.2.2.2.France telmisartan market, by distribution channel
6.3.2.3.UK
6.3.2.3.1.UK telmisartan market, by indication
6.3.2.3.2.UK telmisartan market, by distribution channel
6.3.2.4.Italy
6.3.2.4.1.Italy telmisartan market, by indication
6.3.2.4.2.Italy telmisartan market, by distribution channel
6.3.2.5.Spain
6.3.2.5.1.Spain telmisartan market, by indication
6.3.2.5.2.Spain telmisartan market, by distribution channel
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe telmisartan market, by indication
6.3.2.6.2.Rest of Europe telmisartan market, by distribution channel
6.3.3.Europe market size and forecast, by indication
6.3.4.Europe market size and forecast, by distribution channel
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.Japan
6.4.2.1.1.Japan telmisartan market, by indication
6.4.2.1.2.Japan telmisartan market, by distribution channel
6.4.2.2.China
6.4.2.2.1.China telmisartan market, by indication
6.4.2.2.2.China telmisartan market, by distribution channel
6.4.2.3.Australia
6.4.2.3.1.Australia telmisartan market, by indication
6.4.2.3.2.Australia telmisartan market, by distribution channel
6.4.2.4.India
6.4.2.4.1.India telmisartan market, by indication
6.4.2.4.2.India telmisartan market, by distribution channel
6.4.2.5.South Korea
6.4.2.5.1.South Korea telmisartan market, by indication
6.4.2.5.2.South Korea telmisartan market, by distribution channel
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific telmisartan market, by indication
6.4.2.6.2.Rest of Asia-Pacific telmisartan market, by distribution channel
6.4.3.Asia-Pacific market size and forecast, by indication
6.4.4.Asia-Pacific market size and forecast, by distribution channel
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil telmisartan market, by indication
6.5.2.1.2.Brazil telmisartan market, by distribution channel
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia telmisartan market, by indication
6.5.2.2.2.Saudi Arabia telmisartan market, by distribution channel
6.5.2.3.South Africa
6.5.2.3.1.South Africa telmisartan market, by indication
6.5.2.3.2.South Africa telmisartan market, by distribution channel
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA telmisartan market, by indication
6.5.2.4.2.Rest of LAMEA telmisartan market, by distribution channel
6.5.3.LAMEA market size and forecast, by indication
6.5.4.LAMEA market size and forecast, by distribution channel
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.AUROBINDO PHARMA
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance.
7.3.BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.CIPLA INC.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.GLAXOSMITHKLINE PLC (GSK)
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance.
7.6.MYLAN N.V.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.SANOFI
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.ZYDUS CADILA
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.
7.10.6.Key strategic moves and developments
1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five force analysis
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Surge in geriatric population worldwide
3.5.1.2.Increase in healthcare expenditure worldwide coupled with surge in awareness towards treatment of high blood pressure
3.5.1.3.Rise in prevalence of hypertension across the globe
3.5.2.Restraint
3.5.2.1.Drug shortages of telmisartan tablets
3.5.3.Opportunities
3.5.3.1.High growth potential in developing economies
3.5.4.Impact analysis
3.6.Covid-19 Impact analysis on telmisartan market
CHAPTER 4:TELMISARTAN MARKET, BY INDICATION
4.1.Overview
4.1.1.Market size and forecast
4.2.Hypertension
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Cardiovascular risk reduction
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
CHAPTER 5:TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital pharmacies
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Drug stores and retail pharmacies
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Online pharmacies
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
CHAPTER 6:TELMISARTAN MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. telmisartan market, by indication
6.2.2.1.2.U.S. telmisartan market, by distribution channel
6.2.2.2.Canada
6.2.2.2.1.Canada telmisartan market, by indication
6.2.2.2.2.Canada telmisartan market, by distribution channel
6.2.2.3.Mexico
6.2.2.3.1.Mexico telmisartan market, by indication
6.2.2.3.2.Mexico telmisartan market, by distribution channel
6.2.3.North America market size and forecast, by indication
6.2.4.North America market size and forecast, by distribution channel
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany
6.3.2.1.1.Germany telmisartan market, by indication
6.3.2.1.2.Germany telmisartan market, by distribution channel
6.3.2.2.France
6.3.2.2.1.France telmisartan market, by indication
6.3.2.2.2.France telmisartan market, by distribution channel
6.3.2.3.UK
6.3.2.3.1.UK telmisartan market, by indication
6.3.2.3.2.UK telmisartan market, by distribution channel
6.3.2.4.Italy
6.3.2.4.1.Italy telmisartan market, by indication
6.3.2.4.2.Italy telmisartan market, by distribution channel
6.3.2.5.Spain
6.3.2.5.1.Spain telmisartan market, by indication
6.3.2.5.2.Spain telmisartan market, by distribution channel
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe telmisartan market, by indication
6.3.2.6.2.Rest of Europe telmisartan market, by distribution channel
6.3.3.Europe market size and forecast, by indication
6.3.4.Europe market size and forecast, by distribution channel
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.Japan
6.4.2.1.1.Japan telmisartan market, by indication
6.4.2.1.2.Japan telmisartan market, by distribution channel
6.4.2.2.China
6.4.2.2.1.China telmisartan market, by indication
6.4.2.2.2.China telmisartan market, by distribution channel
6.4.2.3.Australia
6.4.2.3.1.Australia telmisartan market, by indication
6.4.2.3.2.Australia telmisartan market, by distribution channel
6.4.2.4.India
6.4.2.4.1.India telmisartan market, by indication
6.4.2.4.2.India telmisartan market, by distribution channel
6.4.2.5.South Korea
6.4.2.5.1.South Korea telmisartan market, by indication
6.4.2.5.2.South Korea telmisartan market, by distribution channel
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific telmisartan market, by indication
6.4.2.6.2.Rest of Asia-Pacific telmisartan market, by distribution channel
6.4.3.Asia-Pacific market size and forecast, by indication
6.4.4.Asia-Pacific market size and forecast, by distribution channel
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil telmisartan market, by indication
6.5.2.1.2.Brazil telmisartan market, by distribution channel
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia telmisartan market, by indication
6.5.2.2.2.Saudi Arabia telmisartan market, by distribution channel
6.5.2.3.South Africa
6.5.2.3.1.South Africa telmisartan market, by indication
6.5.2.3.2.South Africa telmisartan market, by distribution channel
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA telmisartan market, by indication
6.5.2.4.2.Rest of LAMEA telmisartan market, by distribution channel
6.5.3.LAMEA market size and forecast, by indication
6.5.4.LAMEA market size and forecast, by distribution channel
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.AUROBINDO PHARMA
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance.
7.3.BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.CIPLA INC.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.GLAXOSMITHKLINE PLC (GSK)
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance.
7.6.MYLAN N.V.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.SANOFI
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.ZYDUS CADILA
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.
7.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL TELMISARTAN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 02.TELMISARTAN MARKET FOR HYPERTENSION, BY REGION, 2019–2027 ($MILLION)
TABLE 03.TELMISARTAN MARKET FOR CARDIOVASCULAR RISK REDUCTION, BY REGION, 2019–2027 ($MILLION)
TABLE 04.TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 05.HOSPITAL PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.DRUG STORES AND RETAIL PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 07.ONLINE PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 08.TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 09.NORTH AMERICA TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 10.U.S. TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 11.U.S. TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 12.CANADA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 13.CANADA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 14.MEXICO TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 15.MEXICO TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 16.NORTH AMERICA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 17.NORTH AMERICA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 18.EUROPE TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.GERMANY TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 20.GERMANY TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 21.FRANCE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 22.FRANCE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 23.UK TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 24.UK TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 25.ITALY TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 26.ITALY TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 27.SPAIN TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 28.SPAIN TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 29.REST OF EUROPE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 30.REST OF EUROPE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 31.EUROPE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 32.EUROPE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 33.ASIA-PACIFIC TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 34.JAPAN TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 35.JAPAN TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 36.CHINA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 37.CHINA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 38.AUSTRALIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 39.AUSTRALIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 40.INDIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 41.INDIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 42.SOUTH KOREA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 43.SOUTH KOREA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 44.REST OF ASIA-PACIFIC TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 45.REST OF ASIA-PACIFIC TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 46.ASIA-PACIFIC TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 47.ASIA-PACIFIC TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 48.LAMEA TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 49.BRAZIL TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 50.BRAZIL TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 51.SAUDI ARABIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 52.SAUDI ARABIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 53.SOUTH AFRICA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 54.SOUTH AFRICA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 55.REST OF LAMEA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 56.REST OF LAMEA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 57.LAMEA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 58.LAMEA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 59.ABBOTT: COMPANY SNAPSHOT
TABLE 60.ABBOTT: OERATING SEGMENT
TABLE 61.ABBOTT: PRODUCT PORTFOLIO
TABLE 62.AUROBINDO: COMPANY SNAPSHOT
TABLE 63.AUROBINDO: PRODUCT PORTFOLIO
TABLE 64.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 65.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 66.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 01.CIPLA: COMPANY SNAPSHOT
TABLE 02.CIPLA: OPERATING SEGMENTS
TABLE 03.CIPLA: PRODUCT PORTFOLIO
TABLE 04.GSK: COMPANY SNAPSHOT
TABLE 05.GSK: OPERATING SEGMENTS
TABLE 06.GSK: PRODUCT PORTFOLIO
TABLE 07.MYLAN: COMPANY SNAPSHOT
TABLE 08.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 09.MYLAN: PRODUCT PORTFOLIO
TABLE 10.SANOFI: COMPANY SNAPSHOT
TABLE 11.SANOFI: OERATING SEGMENT
TABLE 12.SANOFI: PRODUCT PORTFOLIO
TABLE 13.SUN PHARMA: COMPANY SNAPSHOT
TABLE 14.SUN PHARMA: OPERATING SEGMENTS
TABLE 15.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 16.TEVA: COMPANY SNAPSHOT
TABLE 17.TEVA: OPERATING SEGMENTS
TABLE 18.TEVA: PRODUCT PORTFOLIO
TABLE 19.ZYDUS: COMPANY SNAPSHOT
TABLE 20.ZYDUS: OPERATING SEGMENTS
TABLE 21.ZYDUS: PRODUCT PORTFOLIO
TABLE 22.ZYDUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 01.GLOBAL TELMISARTAN MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 02.TELMISARTAN MARKET FOR HYPERTENSION, BY REGION, 2019–2027 ($MILLION)
TABLE 03.TELMISARTAN MARKET FOR CARDIOVASCULAR RISK REDUCTION, BY REGION, 2019–2027 ($MILLION)
TABLE 04.TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 05.HOSPITAL PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.DRUG STORES AND RETAIL PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 07.ONLINE PHARMACIES TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 08.TELMISARTAN MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 09.NORTH AMERICA TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 10.U.S. TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 11.U.S. TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 12.CANADA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 13.CANADA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 14.MEXICO TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 15.MEXICO TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 16.NORTH AMERICA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 17.NORTH AMERICA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 18.EUROPE TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.GERMANY TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 20.GERMANY TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 21.FRANCE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 22.FRANCE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 23.UK TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 24.UK TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 25.ITALY TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 26.ITALY TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 27.SPAIN TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 28.SPAIN TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 29.REST OF EUROPE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 30.REST OF EUROPE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 31.EUROPE TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 32.EUROPE TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 33.ASIA-PACIFIC TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 34.JAPAN TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 35.JAPAN TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 36.CHINA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 37.CHINA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 38.AUSTRALIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 39.AUSTRALIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 40.INDIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 41.INDIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 42.SOUTH KOREA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 43.SOUTH KOREA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 44.REST OF ASIA-PACIFIC TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 45.REST OF ASIA-PACIFIC TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 46.ASIA-PACIFIC TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 47.ASIA-PACIFIC TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 48.LAMEA TELMISARTAN MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 49.BRAZIL TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 50.BRAZIL TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 51.SAUDI ARABIA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 52.SAUDI ARABIA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 53.SOUTH AFRICA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 54.SOUTH AFRICA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 55.REST OF LAMEA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 56.REST OF LAMEA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 57.LAMEA TELMISARTAN MARKET, BY INDICATION, 2019–2027
TABLE 58.LAMEA TELMISARTAN MARKET, BY DISTRIBUTION CHANNEL, 2019–2027
TABLE 59.ABBOTT: COMPANY SNAPSHOT
TABLE 60.ABBOTT: OERATING SEGMENT
TABLE 61.ABBOTT: PRODUCT PORTFOLIO
TABLE 62.AUROBINDO: COMPANY SNAPSHOT
TABLE 63.AUROBINDO: PRODUCT PORTFOLIO
TABLE 64.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 65.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 66.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 01.CIPLA: COMPANY SNAPSHOT
TABLE 02.CIPLA: OPERATING SEGMENTS
TABLE 03.CIPLA: PRODUCT PORTFOLIO
TABLE 04.GSK: COMPANY SNAPSHOT
TABLE 05.GSK: OPERATING SEGMENTS
TABLE 06.GSK: PRODUCT PORTFOLIO
TABLE 07.MYLAN: COMPANY SNAPSHOT
TABLE 08.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 09.MYLAN: PRODUCT PORTFOLIO
TABLE 10.SANOFI: COMPANY SNAPSHOT
TABLE 11.SANOFI: OERATING SEGMENT
TABLE 12.SANOFI: PRODUCT PORTFOLIO
TABLE 13.SUN PHARMA: COMPANY SNAPSHOT
TABLE 14.SUN PHARMA: OPERATING SEGMENTS
TABLE 15.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 16.TEVA: COMPANY SNAPSHOT
TABLE 17.TEVA: OPERATING SEGMENTS
TABLE 18.TEVA: PRODUCT PORTFOLIO
TABLE 19.ZYDUS: COMPANY SNAPSHOT
TABLE 20.ZYDUS: OPERATING SEGMENTS
TABLE 21.ZYDUS: PRODUCT PORTFOLIO
TABLE 22.ZYDUS: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.GLOBAL TELMISARTAN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.LOW THREAT OF SUBSTITUTES
FIGURE 04.HIGH THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.COMPARATIVE ANALYSIS OF TELMISARTAN MARKET FOR HYPERTENSION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF TELMISARTAN MARKET FOR CARDIOVASCULAR RISK REDUCTION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF ONLINE PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 13.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 14.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 15.ABBOTT: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 16.AUROBINDO: NET SALES, 2018–2020 ($MILLION)
FIGURE 17.AUROBINDO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 18.BOEHRINGER INGELHEIM: NET SALES, 2017–2019 ($MILLION)
FIGURE 19.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 20.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 01.CIPLA: NET SALES, 2017–2019 ($MILLION)
FIGURE 02.CIPLA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 03.CIPLA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 04.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 05.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 06.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 07.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 08.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 09.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 10.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 11.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 12.SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 13.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 14.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 15.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 16.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 17.ZYDUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 18.ZYDUS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 19.ZYDUS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 01.GLOBAL TELMISARTAN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.LOW THREAT OF SUBSTITUTES
FIGURE 04.HIGH THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.COMPARATIVE ANALYSIS OF TELMISARTAN MARKET FOR HYPERTENSION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF TELMISARTAN MARKET FOR CARDIOVASCULAR RISK REDUCTION, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF ONLINE PHARMACIES TELMISARTAN MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
FIGURE 13.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 14.ABBOTT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 15.ABBOTT: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 16.AUROBINDO: NET SALES, 2018–2020 ($MILLION)
FIGURE 17.AUROBINDO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 18.BOEHRINGER INGELHEIM: NET SALES, 2017–2019 ($MILLION)
FIGURE 19.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 20.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 01.CIPLA: NET SALES, 2017–2019 ($MILLION)
FIGURE 02.CIPLA: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 03.CIPLA: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 04.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 05.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 06.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 07.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 08.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 09.SANOFI.: NET SALES, 2017–2019 ($MILLION)
FIGURE 10.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 11.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 12.SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 13.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 14.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 15.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 16.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 17.ZYDUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 18.ZYDUS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 19.ZYDUS: REVENUE SHARE, BY REGION, 2020 (%)
